Summit Therapeutics
$16.69Change from previous close: −1.30%Absolute change: −$0.22
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $13.31B
- Enterprise value
- $12.64B
- Forward P/E
- -14.6
- Price/book
- 21.0
- EV/EBITDA
- -14.5
Profitability and growth
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -192.5%
- ROA
- -101.6%
Financial health
- Total cash
- $690.68M
- Total debt
- $20.38M
- Debt/equity
- 0.03
- Current ratio
- 6.96
- Quick ratio
- 6.67
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $29.69
- Median price target
- $32.67
- High price target
- $43.01
- Low price target
- $11.53
- Analysts with a price target
- 13
- Consensus
- Buy
- Forward EPS
- -$1.14
- EPS estimate, current year
- -$0.85
Shares and trading
- Beta
- -1.24
- Average volume
- 5.58M
- Shares outstanding
- 797.75M
- Float
- 152.28M
- Institutional ownership
- 17.6%
- Insider ownership
- 80.9%
- Short interest (% of float)
- 26.3%
- Short ratio (days)
- 6.44